Regorafenib medication experience sharing and guidance for patients with advanced liver cancer

Regorafenib is a multi-target tyrosine kinase inhibitor that has been widely used in the treatment of advanced hepatocellular carcinoma (HCC). For patients with advanced liver cancer, regorafenib is often used as a second-line option after first-line treatment failure. It can effectively delay tumor progression and improve patient survival. When patients use regorafenib, they should be under the guidance of a professional doctor and a reasonable treatment plan should be formulated based on individual conditions.

Medication experience shows that the starting dose of regorafenib is generally 160mg per day, administered orally, with a 3weeks of medication1weeks off. Patients need to be closely monitored for drug-related side effects, especially common adverse reactions such as hypertension, hand-foot syndrome, fatigue, and abnormal liver function. In response to these side effects, doctors will adjust the dosage or provide symptomatic treatment according to the patient's tolerance to ensure the continuity and safety of treatment.

Patients with advanced liver cancer are often accompanied by impaired liver function, and the use of regorafenib requires special attention to liver function monitoring. Regular detection of liver enzyme levels, bilirubin and other indicators and timely detection of liver function fluctuations are crucial to preventing severe hepatotoxic reactions. In addition, patients should maintain good living habits, eat a reasonable diet, and avoid drinking alcohol and using drugs that may damage the liver to reduce the burden on the liver and assist drug treatment.

Finally, patients and their families should strengthen communication during the medication process, provide timely feedback on discomfort symptoms, and cooperate with doctors to make individualized adjustments. Through scientific and standardized treatment and close monitoring, most patients can better tolerate regorafenib and improve their quality of life and treatment effect. With the accumulation of clinical experience, the application of regorafenib in advanced liver cancer will become more mature and bring more hope to patients.

Reference materials:https://www.stivarga-us.com/